Suven Life Sciences Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Public

  • Employees
  • 132

Employees

  • Stock Symbol
  • 530239

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.59
  • (As of Friday Closing)

Suven Life Sciences General Information

Description

Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company's only segment is providing Research and Development services. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API) Speciality chemicals, and formulated drugs under contract research and manufacturing services. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.

Contact Information

Website
www.suven.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Corporate Office
  • 6th Floor, SDE Serene Chambers
  • Avenue-7, Road No. 5, Banjara Hills
  • Hyderabad, Telangana 500034
  • India
+91 040 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Suven Life Sciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.59 $1.64 $0.73 - $1.74 $346M 218M 39.8K -$0.06

Suven Life Sciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 237,085 237,085 127,491 175,521
Revenue 1,412 1,412 1,686 1,590
EBITDA (13,993) (13,993) (14,677) (15,864)
Net Income (12,693) (12,693) (14,729) (16,374)
Total Assets 34,164 34,164 47,370 14,247
Total Debt 85 85 196 423
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Suven Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Suven Life Sciences‘s full profile, request access.

Request a free trial

Suven Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company's geographical segment includes India;
Pharmaceuticals
Hyderabad, India
132 As of 2023
00000 0000-00-00
000000000000

0000 0

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
000000000000000
Mumbai, India
00000 As of 0000
00000000000

000 00

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
000000000000000
Mumbai, India
00000 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Suven Life Sciences Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ipca Laboratories Corporation Mumbai, India 00000 00000000000
Sun Pharmaceutical Industries Corporation Mumbai, India 00000 000000000000
Wockhardt Corporation Mumbai, India 0000 000.00 000000000 000.00
Zydus Lifesciences Corporation Ahmedabad, India 00000 000.00 0000 000.00
Evotec Formerly PE-Backed Hamburg, Germany 0000 00000 000000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

Suven Life Sciences Patents

Suven Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023207848-A1 Heteroalicyclic derivatives and their use in the treatment of cns disorders Pending 11-Jan-2022
AU-2023207844-A1 Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-ht4 receptor agonists Pending 11-Jan-2022
JP-2023506724-A Treatment of psycho-behavioral symptoms in people with dementia Pending 02-Dec-2019 0000000000 0
US-20220409614-A1 Treating behavioral and psychological symptoms in dementia patients Pending 02-Dec-2019 000000000
AU-2020398082-A8 Treating behavioral and psychological symptoms in dementia patients Pending 02-Dec-2019 A61K31/496
To view Suven Life Sciences’s complete patent history, request access »

Suven Life Sciences Executive Team (3)

Name Title Board Seat Contact Info
Venkateswarlu Jasti Chief Executive Officer, Chairman & Board Member
Venkatraman Sunder Director and Vice President, Strategy and Corporate Affairs
You’re viewing 2 of 3 executive team members. Get the full list »

Suven Life Sciences Board Members (5)

Name Representing Role Since
0000000000 000000 Suven Life Sciences Board Member 000 0000
0000000000000 0000 Suven Life Sciences Independent Non-Executive Director 000 0000
000000000 00000 Suven Life Sciences Board Member 000 0000
0000000000000 0000 Suven Life Sciences Chief Executive Officer, Chairman & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Suven Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Suven Life Sciences Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Rising Pharma Holdings 07-Mar-2019 00000 0000 Drug Discovery 000000000
To view Suven Life Sciences’s complete investments history, request access »

Suven Life Sciences ESG

Risk Overview

Risk Rating

Updated October, 01, 2023

37.45 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Suven Life Sciences’s complete esg history, request access »

Suven Life Sciences FAQs

  • When was Suven Life Sciences founded?

    Suven Life Sciences was founded in 1989.

  • Who is the CEO of Suven Life Sciences?

    Venkateswarlu Jasti is the CEO of Suven Life Sciences.

  • Where is Suven Life Sciences headquartered?

    Suven Life Sciences is headquartered in Hyderabad, India.

  • What is the size of Suven Life Sciences?

    Suven Life Sciences has 132 total employees.

  • What industry is Suven Life Sciences in?

    Suven Life Sciences’s primary industry is Pharmaceuticals.

  • Is Suven Life Sciences a private or public company?

    Suven Life Sciences is a Public company.

  • What is Suven Life Sciences’s stock symbol?

    The ticker symbol for Suven Life Sciences is 530239.

  • What is the current stock price of Suven Life Sciences?

    As of 12-Jul-2024 the stock price of Suven Life Sciences is $1.59.

  • What is the current market cap of Suven Life Sciences?

    The current market capitalization of Suven Life Sciences is $346M.

  • What is Suven Life Sciences’s current revenue?

    The trailing twelve month revenue for Suven Life Sciences is $1.41M.

  • Who are Suven Life Sciences’s competitors?

    Ipca Laboratories, Sun Pharmaceutical Industries, Wockhardt, Zydus Lifesciences, and Evotec are some of the 11 competitors of Suven Life Sciences.

  • What is Suven Life Sciences’s annual earnings per share (EPS)?

    Suven Life Sciences’s EPS for 12 months was -$0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »